Clinical trial
Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients…
NCT00279214 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00279214 |
|---|---|
| Title | Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock |
| Official title | An Evaluation of Vasopressor Requirement, Hemodynamic Response and Measures of Tissue Perfusion With the Administration of Drotrecogin Alfa (Activated) as Part of Physician-Directed Therapy in Patients With Septic Shock |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Sepsis, Septic Shock |
| Intervention type | Drug |
| Interventions | drotrecogin alfa (activated) |
| Enrollment | 43 |
| Start date | Nov 1, 2005 |
| Completion | Nov 1, 2007 |
| First posted | Jan 19, 2006 |
| Last update posted | Sep 2, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: